Mr. Thomas Mehrling reports

HELIX BIOPHARMA CORP. APPOINTS MARKUS LOEFFLER, MD, MBA, AS CHIEF MEDICAL OFFICER TO SUPPORT NEXT PHASE OF CLINICAL DEVELOPMENT

Helix BioPharma Corp. has appointed Dr. Markus Loeffler, MD, MBA, as chief medical officer of the company.

Dr. Loeffler's appointment comes as Helix prepares to enter a more execution-focused phase of clinical development, with multiple programs approaching key regulatory and clinical milestones. As CMO, he will lead the strategy and execution of Helix's clinical programs, including the planned phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab in first-line non-small cell lung cancer (NSCLC), while guiding Leumuna toward clinical development for leukemia relapse following allogeneic stem cell transplantation.

"I've had the privilege of working with Markus before and I have seen firsthand his ability to translate innovative science into well-executed clinical development programs," said Thomas Mehrling, MD, PhD, chief executive officer of Helix. "He is an outstanding clinical development leader with a strong track record of advancing innovative oncology therapies through the development pathway. His expertise will be instrumental as we advance L-DOS47 into its next stage of clinical development and prepare Leumuna to enter the clinic."

Dr. Loeffler is a physician-scientist and biotechnology executive bringing more than three decades of leadership in oncology drug development. He has extensive experience advancing oncology therapeutics, including small molecules, biologics, antibody-drug conjugates (ADCs), radiopharmaceuticals and immunotherapies, from early clinical development through phase III and regulatory approval. Throughout his career, he has held senior clinical development and CMO roles at leading biotechnology and pharmaceutical companies, including Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals and SK Life Science. Dr. Loeffler also led the pivotal phase III clinical program for Lutathera, which was subsequently approved for the treatment of certain gastroenteropancreatic neuroendocrine tumours.

Dr. Loeffler said: "I'm excited to join Helix at such an important stage in its evolution. The company's pipeline combines strong scientific foundations with clear clinical development opportunities. I am particularly enthused by the opportunity to advance L-DOS47 in combination with checkpoint inhibition and to bring Leumuna toward its first clinical evaluation. I look forward to working alongside the team to translate these programs into meaningful new treatment options for patients with difficult-to-treat cancers."

About Helix BioPharma Corp.

Helix BioPharma is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The company's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include Leumuna, a pre-IND (investigational new drug) oral immune checkpoint modulator for posttransplant leukemia relapse, and Gemceda, a pre-IND gemcitabine prodrug for advanced solid tumours.

Helix BioPharma's common shares are listed on the Toronto Stock Exchange, quoted on the OTC Pink Market and listed on the Frankfurt Stock Exchange.

We seek Safe Harbor.